Benzodiazepine discontinuation with prolonged-release melatonin: Hints from a German longitudinal prescription database

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 1, 2012, Pages 9-16

  Kunz, Dieter ^a   Bineau, Sébastien ^b   Maman, Khaled ^c   Milea, Dominique ^b   Toumi, Mondher ^d  

^a MARTIN LUTHER KRANKENHAUS   (Germany)

^b Lundbeck   (France)

^c Creativ Research   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Benzodiazepines; Drug discontinuation; Insomnia; Patient profile; Prolonged release melatonin

Indexed keywords

BENZODIAZEPINE; MELATONIN;

ARTICLE; BACKACHE; CLINICAL PRACTICE; CONTROLLED RELEASE FORMULATION; DATA EXTRACTION; DEPRESSION; DISORDERS OF LIPOPROTEIN METABOLISM; DRUG APPROVAL; DRUG WITHDRAWAL; FEMALE; GERMANY; HUMAN; HYPERTENSION; HYPNOSIS; INSOMNIA; ISCHEMIC HEART DISEASE; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT DURATION;

AGED; BENZODIAZEPINES; DELAYED-ACTION PREPARATIONS; FEMALE; GERMANY; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MELATONIN; MIDDLE AGED; RETROSPECTIVE STUDIES; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 83455210179     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.638284     Document Type: Article

References (28)

1. National Institutes of Health NIH State-of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. Available from: http://consensus.nih.gov/previous. htm 2005.22:1-30
2. Zisapel N. Sleep and sleep disturbances: biological basis and clinical implications. Cell Mol Life Sci 2007;64:1174-86
3. Ohayon MM, Zulley J, Guilleminault C, et al. How age and daytime activities are related to insomnia in the general population: consequences for older people. J Am Geriatr Soc 2001;49:360-6
4. Hajak G. Epidemiology of severe insomnia and its consequences in Germany. Eur Arch Psychiatry Clin Neurosci 2001;251:49-56
5. Hardeland R. New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists. Neuropsychiatr Dis Treat 2009;5:341-54
6. Daley M, Morin CM, LeBlanc M, et al. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep 2009;32:55-64
7. Glass J, Lanctot KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005;331:1169
8. Lieberman JA. Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care. Prim Care Companion J Clin Psychiatry 2007;9:25-31
9. Bourin M. The problems with the use of benzodiazepines in elderly patients. Encephale 2010;36:340-7
10. Morin CM, Belanger L, Bastien C, et al. Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival analysis of relapse. Behav Res Ther 2005;43:1-14
11. Lemoine P, Ni T, Laudon M, et al. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 2007;16:372-80
12. Wade AG, Ford I, Crawford G, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007;23:2597-605
13. Luthringer R, Muzet M, Zisapel N, et al. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol 2009;24:239-49
14. Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med 2010;8:51
15. Melatonin for primary insomnia? Drug Ther Bull 2009;47:74-7
16. Becher H, Kostev K, Schroder-Bernhardi D. Validity and representativeness of the "Disease Analyzer" patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 2009;47:617-26
17. ICD-10 codes German Modification 2007. 2007
18. Anatomical classification guidelines 2007. European Pharmaceutical Research Association (EPHMRA), 2007
19. Deutsche Hauptstelle fur Suchtfragen Pressekonferenz am 7.4.2010 in BerlinVorstellung des Jahrbuchs SUCHT 2010. Available from: http:// www.sucht. lawicki.de/index.php?option=com content&view=article&id=491: Jahrbuchsucht- 2010-suchtmittelkonsum-bleibtstabil- auf-extrm-hohem-niveau- &catid-1: aktuelle-nachrichten<mid=18 2010
20. Schwabe U, Paffrath D. Arzneimittelverordnungsreport 2009. Springer Medizin Verlag; Heidelberg: 2009
21. Deutsche Hauptstelle fur SuchtfragenDHS Jahrbuch SUCHT 2010. Available from: http://www.dhs.de 2010
22. Garfinkel D, Zisapel N, Wainstein J, et al. Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Arch Intern Med 1999;159:2456-60
23. Dagan Y, Zisapel N, Nof D, et al. Rapid reversal of tolerance to benzodiazepine hypnotics by treatment with oral melatonin: a case report. Eur Neuropsychopharmacol 1997;7:157-60
24. Vissers FH, Knipschild PG, Crebolder HF. Is melatonin helpful in stopping the long-term use of hypnotics? A discontinuation trial. Pharm World Sci 2007;29:641-6
25. Aldhous M, Franey C, Wright J, et al. Plasma concentrations of melatonin in man following oral absorption of different preparations. Br J Clin Pharmacol 1985;19:517-21
26. Oude Voshaar RC, Gorgels WJ, Mol AJ, et al. Long-term outcome of two forms of randomised benzodiazepine discontinuation. Br J Psychiatry 2006;188:188-9
27. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR--Procedural-steps-taken-and-scientific-information-after-authorisation/ human/000695/ WC500026810.pdf 2011
28. Verdoux H, Gaudron Y, Tournier M. Transition in care in persons with antidepressant prescription in naturalistic conditions. Fam Pract 2011;28:400-5